Esperion Therapeutics | ESPR


Peers Price Chg Day Year Date
Daiichi Sankyo 3,672.00 51.00 1.41% -36.40% Sep/08
AbbVie 212.56 -0.44 -0.21% 9.95% Sep/05
Alnylam Pharmaceuticals 452.00 -1.54 -0.34% 83.16% Sep/05
Amgen 283.64 3.54 1.26% -11.49% Sep/05
Amarin 15.33 0.30 2.00% 27.64% Sep/05
Biogen 140.67 0.73 0.52% -30.02% Sep/05
BioMarin Pharmaceutical 57.77 1.02 1.80% -31.29% Sep/05
Cipla 1,564.70 11.30 0.73% -3.42% Sep/08
CSL 213.50 4.25 2.03% -28.93% Sep/08
Cytokinetics 53.01 3.26 6.55% -2.00% Sep/05
Geron 1.40 0.02 1.45% -67.06% Sep/05
Grifols 10.13 0.23 2.32% 19.32% Sep/05
Halozyme Therapeutics 74.93 1.53 2.08% 26.55% Sep/05
Ionis Pharmaceuticals 61.23 1.88 3.17% 30.58% Sep/05
Eli Lilly 727.21 -15.70 -2.11% -19.48% Sep/05
Merck 84.71 0.66 0.79% -28.14% Sep/05
Moderna 25.14 0.86 3.54% -65.54% Sep/05
Pfizer 24.88 0.34 1.39% -12.95% Sep/05
PTC Therapeutics 57.26 -0.75 -1.29% 81.55% Sep/05
Regeneron Pharmaceuticals 573.38 6.16 1.09% -49.30% Sep/05
Sanofi 79.50 0.54 0.68% -24.83% Sep/06
Sarepta Therapeutics 18.71 0.25 1.35% -85.49% Sep/05
United Therapeutics 400.52 20.05 5.27% 15.88% Sep/05

Indexes Price Day Year Date
USND 21700 -7.31 -0.03% 30.01% Sep/05
US2000 2391 11.44 0.48% 14.33% Sep/05

Esperion Therapeutics traded at $2.79 this Tuesday April 9th, decreasing $0.24 or 7.92 percent since the previous trading session. Looking back, over the last four weeks, Esperion Therapeutics lost 31.60 percent. Over the last 12 months, its price rose by 103.65 percent. Looking ahead, we forecast Esperion Therapeutics to be priced at 2.77 by the end of this quarter and at 2.70 in one year, according to Trading Economics global macro models projections and analysts expectations.

Esperion Therapeutics, Inc. is a lipid management company. The Company is a pharmaceutical company focused on developing and commercializing oral, once-daily, non-statin medicines for patients struggling with elevated low-density lipoprotein cholesterol (LDL-C). Its bempedoic acid and the bempedoic acid / ezetimibe combination tablets are oral, once-daily, non-statin, LDL-C lowering medicines for patients with atherosclerotic cardiovascular disease (ASCVD), or heterozygous familial hypercholesterolemia (HeFH). Its products include NEXLETOL, NILEMDO, NEXLIZET and NUSTENDI. NEXLETOL and NILEMDO are ATP Citrate Lyase (ACL) inhibitor that lowers LDL-C by reducing cholesterol biosynthesis and up-regulating the LDL receptors. NEXLIZET and NUSTENDI contains bempedoic acid and ezetimibe and lowers elevated LDL-C through complementary mechanisms of action by inhibiting cholesterol synthesis in the liver and absorption in the intestine.